Skip to content
Screener

Organon OGN Q4 2025 Annual earnings

Reported February 12, 2026 · Before market open

Revenue$1.5BMiss by $27.8M
EPS$0.63Miss by $0.10
Revenue estimate$1.5B
EPS estimate$0.73

Next report

Nov 9, 2026 (in a month)
Revenue estimate$1.6B
EPS estimate$0.88

Financials

Q4 2025

Income statement

See full
Revenue$1.5B-5.3%
Gross profit$741.0M-17.3%

Balance sheet

See full
Cash & equivalents$574.0M-15.0%
Total debt$8.8B-2.6%
Total equity$752.0M+59.3%
Total assets$12.9B-1.8%

Cash flow

See full
Operating cash flow$141.0M-63.8%
CapEx$45.0M-18.2%
Free cash flow$96.0M-71.3%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$1.86B-51.5%
Enterprise value$10.09B-17.3%
P/S0.3×-0.3×

Profitability

See full
Gross margin53.3%-4.7pp
FCF margin8.7%-3.3pp

Returns & leverage

See full
Debt / equity11.7×-7.4×
Current ratio1.8×+0.2×

Segments

By product

See full
Nexplanon/Implanon NXT$210.0M-18.9%
Zetia$90.0M+16.9%
Other$85.0M-2.3%
Other Non-Opiod Pain, Bone and Dermatology$72.0M—
Arcoxia$70.0M+18.6%

By geography

See full
Europe and Canada$406.0M-3.3%
Latin America, Middle East, Russia, and Africa$262.0M-1.5%
Asia Pacific and Japan$248.0M+1.6%
Other$17.0M-48.5%

FAQ

When did Organon report Q4 2025 earnings?
Organon (OGN) reported Q4 2025 earnings on February 12, 2026 before market open.
What were Organon's Q4 2025 revenue and EPS?
Organon reported revenue of $1.5B and eps of $0.63 for Q4 2025.
Did Organon beat estimates in Q4 2025?
Revenue missed the consensus estimate of $1.5B by $27.8M. EPS missed the consensus estimate of $0.73 by $0.10.
How did Organon's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 5.3% from $1.6B a year earlier and eps declined 30.0% from $0.90.
Where can I find Organon's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001104659-26-013888) and the 10-K periodic report (0001628280-26-011125) directly on SEC EDGAR. The filing index links above go to sec.gov.